Colon Cancer



SAHA is a HDAC inhibitor. SAHA may also block angiogenic signaling by inhibiting the VEGF receptors expression and also reduce circulating levels of inflammatory cytokines. In this study SAHA is administered with Hydroxychloroquine in patients with advanced solid tumors

Type(s) of Cancer: Colon Cancer
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798